Disease area studied	Abbreviated title	Phase	Study ID	Registry database	Study results	Lay summary	Publication (if available)
Epilepsy	A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age	Phase 3	EP0100 Ongoing	NCT03340064
Epilepsy	A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.	Phase 3	N01009 Completed	NCT00175890 2004-000199-14	LINK PDF	PDF	Pina-Garza et al. Epilepsia;2009;50(5); 1141-1149.
Epilepsy	Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method	Phase 3	N01020 Completed	NCT00160615	LINK PDF		Yagi, K., J Japan Epilepsy Society;2-10-2012; 29;3;441-454 [In Japanese]
Epilepsy	S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy	Phase 4	N01031 Completed	NCT00630968	PDF		Steinhoff et al. Epilepsy Res; 2007;76(1);6-14.
Epilepsy	Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy	Phase 4	N01033 Completed	NCT00643500	PDF		Salas-Puig et al. Rev Neurol; 2004;16-30;38;1117–1122. [in Spanish]
Epilepsy	A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy	Phase 4	N01035 Completed	NCT00631150	PDF
Epilepsy	Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy	Phase 4	N01036 Completed	NCT00160654	LINK PDF		Kwan et al. Epilepsy Behav; 2010;18(1-2);100-105.
Epilepsy	Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy	Phase 4	N01037 Completed	NCT00630357	PDF
Epilepsy	Pharmacokinetic Study of Levetiracetam in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old	Phase 2	N01052 Completed	NCT00544050	PDF		Glauser et al. Epilepsia; 2007;48(6);1117-1122.
Epilepsy	Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures	Phase 3	N01057 Completed	NCT00160550	PDF	PDF	Berkovic et al. Neurology; 2007;69(18);1751-1760.
Epilepsy	Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy	Phase 3	N01061 Completed	NCT00150735	PDF	PDF	Brodie et al. Neurology; 2007;68(6);402-408.
Epilepsy	Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy.	Phase 4	N01085 Completed	NCT00245713	PDF
Anxiety Disorder	Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)	Phase 2	N01086 Completed	NCT00612859	PDF		Stein, M. B. et al., Journal of Clinical Psychiatry;2010;71; 5;627-631
Postherpetic Neuralgia	A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)	Phase 2	N01087 Completed	NCT00160511	PDF
Epilepsy	Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy	Phase 4	N01088 Completed	NCT00630630	PDF
Epilepsy	Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.	Phase 3	N01093 Completed	NCT00150787	PDF		Sethi et al. Neurology; 2007;69(9);937-938.
Epilepsy	Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy	Phase 3	N01099 Completed	NCT00160628	PDF		Heo et al. Seizure; 2007;16(5);402-409.
Epilepsy	Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS	Phase 3	N01102 Completed	NCT00152373		PDF	Wu et al. Epilepsia;2009;50(3) ;398-405.
Epilepsy	A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures	Phase 2	N01103 Completed	NCT00105040 2014-004396-23	LINK PDF		Levisohn et al. Epilepsia;2009;50(11) ;2377-2389.
Parkinson's Disease	Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias	Phase 2	N01105 Completed	NCT00160576	PDF		Ferreira, J. Eur J Neurol;2004;11;Suppl 2;331 8th Congress of the European Federation of Neurological Societies (EFNS), September 4-7, 2004;Paris, France
Epilepsy	Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.	Phase 3	N01127 Completed	NCT00150813	LINK PDF
Tardive Dyskinesia	Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia	Phase 2	N01142 Completed	NCT00175955 2004-001302-27	PDF
Epilepsy	Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures	Phase 3	N01148 Completed	NCT00152516 2004-000200-40	LINK LINK	PDF	Schiemann-Delgado et al.J Child Neurol; 2012;27(1);80-89.
Epilepsy	A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures Except Partial Seizures Evolving to Secondarily Generalized Seizures)	Phase 3	N01159 Completed	NCT01228747 2014-004401-32	LINK LINK	PDF	Wu L., et al. Epilepsia Open 2018; 3(4):474–84
Epilepsy	Safety and Tolerability of Levetiracetam Intravenous 15 Minute Infusion in Subjects Suffering From Partial Onset Seizures	Phase 2	N01166 Completed	NCT00610454	PDF		Baulac et al. Epilepsia; 2007;48(3);589-592.
Epilepsy	Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy	Phase 3	N01175 Completed	NCT00175903 2004-001339-41	LINK PDF		Trinka et al. J Neurol Neurosurg Psychiatry;2013;84(10);1138-1147 Pohlmann-Eden, B., et al. BMC Neurol;2016;16;1;149.
Epilepsy	A Double-blind Confirmatory Trial of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures	Phase 3	N01221 Completed	NCT00280696 2014-004333-57	LINK PDF	PDF	Inoue, Y. et al., Psychiatry Clin Neurosci; 2015;69;10;640-648
Epilepsy	A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures	Phase 3	N01222 Completed	NCT00367432 2014-004334-26	LINK LINK		Yagi, K., Japan J Clin Psychopharm;2016;19; 1027-1040 [In Japanese]
Epilepsy	An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures	Phase 3	N01223 Completed	NCT01063764 2014-004335-39	LINK LINK		Nakamura et al. Brain Nerve; 2013;65(9);1083-1092. [in Japanese]
Epilepsy	A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR	Phase 3	N01235 Completed	NCT00368069 2006-000987-10	LINK LINK		Peltola et al. Epilepsia;2009;50(3); 406-414.
Epilepsy	Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).	Phase 3	N01237 Completed	NCT00291655 2006-000173-29	LINK LINK
Epilepsy	Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam	Phase 4	N01242 Completed	NCT00319605			Matías-Guíu et al. Methods Find Exp Clin Pharmacol;2010; 32(7);507-516.
Epilepsy	Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy	Phase 2	N01274 Completed	NCT00535392 2006-005722-23	LINK LINK	PDF	Weinstock et al. J Child Neurol; 2013;28(11);1423-1429.
Epilepsy	Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy	Phase 2	N01275 Completed	NCT00505934 2007-003517-13	LINK LINK	PDF	Weinstock et al. J Child Neurol; 2013;28(11);1423-1429.
Epilepsy	Conversion to Monotherapy Study With Keppra XR for Partial Seizures	Phase 3	N01280 Completed	NCT00419094 2007-000897-21	LINK LINK		Chung et al. Epilepsy Res; 2012;101(1-2);92-102.
Epilepsy	Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures	Phase 3	N01281 Completed	NCT00419393 2007-000899-17	LINK LINK		Chung, S., et al. Epilepsy Res;2016; 120;7-12
Epilepsy	Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy	Phase 2	N01340 Completed	NCT00961441 2014-004376-39	LINK LINK		Naritoku et al. Epilepsy Curr; 2011;11;1 Suppl.1. 64th Annual Meeting of the American Epilepsy Society (AES), December 3-7, 2010;San Antonio, USA.
Epilepsy	Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures	Phase 4	N01353 Completed	NCT01229735 2014-004402-15	LINK LINK		Lee S.K., et al. Epilepsy Behav 2019; 97:67–74
Epilepsy	An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures	Phase 3	N01361 Completed	NCT01398956 2016-002879-96	LINK LINK		Yagi K et al. Japan J Clin Psychopharm. 2018;21:1609-1622 [In Japanese]
Epilepsy	A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures	Phase 3	N01363 Completed	NCT01292837 2014-004382-25	LINK LINK		Ohtsuka, Y. et al Japan J Clin Psychopharm;2016;19;3;347-359 [in Japanese]
Epilepsy	Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures	Phase 3	N01364 Completed	NCT01954121 2015-004586-84	LINK LINK	PDF	Liao W., et al. J Child Neurol 2020; 33(5) [In Chinese]
Epilepsy	Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subject With Partial Epilepsy	Phase 4	N01367 Completed	NCT01498822 2014-002713-32	LINK LINK		Kim, J. H. et al Epilepsia; 2017;58;4; e70-e74
not applicable (pharmacokinetics study)	Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients	Phase 4	N01373 Completed	NCT01491113	LINK		Yamamoto, J. et al., Clin Drug Investig; 2014;34;11;819-828
Epilepsy	An Open Label Study of Levetiracetam Monotherapy in Newly Diagnosed Epilepsy With Partial Onset Seizure	Phase 3	N01375 Completed	NCT01506882 2014-004377-16	LINK LINK	PDF	Kaneko, S. et al. ,J Japan Epilepsy Society; 2015;32;3;519-532 [ In Japanese]
Epilepsy	An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures	Phase 2	N01378 Completed	NCT01407523	LINK		Inoue, Y. et al., Jpn J Clin Psychopharmacol;2014; 17;413-422 [In Japanese]
Epilepsy	A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy	Phase 3	N157 Completed	NCT00150709	PDF		Glauser et al. Epilepsia;2005;46; Suppl 6;102. 26th International Epilepsy Congress (IEC), August 28-September 1, 2005;Paris, France.
Epilepsy	Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures	Phase 3	N159 Completed	NCT00615615	PDF		Glauser et al. Neurology; 2006;66(11);1654-1660.
Epilepsy	A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures	Phase 2	N164 Completed	NCT00545012	PDF
Epilepsy	Bridging Study of L059 (Levetiracetam) in Patients With Epilepsy by Double Blind Method	Phase 2	N165 Completed	NCT00600509	PDF		Yagi, K. et al., J Japan Epilepsy Society; 7-5-2010;28;1;3-16 [In Japanese]
Epilepsy	Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults	Phase 3	N166 Completed	NCT00150774	PDF		Rosenfeld et al. Epilepsy Res; 2009;85(1);72-80.
Epilepsy	Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy	Phase 3	N167 Completed	NCT00150748 2004-001997-13	LINK PDF		Delanty et al. Epilepsia; 2012;53(1);111-119.

Our Company

Disease Areas

Our Science

UCB Worldwide

Our Products

Newsroom

Patients

Investors

HCP

Clinical Studies

Advantage Hers

Choose a Country

Keppra® (levetiracetam)